🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

36 results for “RIGEL PHARMACEUTICALS INC” Clear

  1. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Covid19

    phase 3 small molecule completed

    1 trial

  2. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    2 trials

  3. Fostamatinib disodium

    RIGEL PHARMACEUTICALS INC

    Immune Thrombocytopenic Purpura

    phase 3 small molecule completed

    3 trials

  4. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  5. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  6. Fostamatinib 150 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule completed

    1 trial

  7. Fostamatinib 150 mg bid

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  8. Fostamatinib Disodium

    RIGEL PHARMACEUTICALS INC

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  9. Fostamatinib Disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  10. Fostamatinib Disodium / R935788

    RIGEL PHARMACEUTICALS INC

    Purpura, Thrombocytopenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  11. Fostamatinib Disodium tablet 100 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  12. Fostamatinib disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  13. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  14. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  15. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Mutant IDH1 Inhibitor Olutasidenib

    phase 2 small molecule active

    1 trial

  16. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  17. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  18. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. Olutasidenib + TMZ

    RIGEL PHARMACEUTICALS INC

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  20. Placebo

    RIGEL PHARMACEUTICALS INC

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  21. Placebo

    RIGEL PHARMACEUTICALS INC

    Asthma

    phase 2 small molecule completed

    1 trial

  22. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  23. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  24. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources